Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 for L-dopa induced dyskinesia in Parkinson's disease
2011-002073-30Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AFQ056 with Placebo (2 arms). Primary endpoint: Anti-dyskinetic efficacy (modified AIMS total score). Started Sep 2011; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-002073-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002073-30.